GleamWall
中文EN

QTTB Q32 Bio Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1661998 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY176.6%
TTM EPS YoY210.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE24.0%
ROA18.2%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets3.2%
Debt / equity0.00x
Current ratio56.34x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.62x
Accruals ratio29.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue———————$0
R&D expense$5.15M$4.26M$3.22M$3.31M$3.56M$5.16M$7.12M$10.54M
SG&A expense$5.51M$4.86M$4.50M$4.54M$4.02M$4.01M$5.10M$3.98M
Operating income-$10.66M-$9.12M-$7.72M$45.88M-$7.58M-$9.17M-$12.23M-$14.53M
Pretax income———$57.73M-$7.39M-$9.49M-$11.03M-$14.17M
Income tax$0$0$0$0$0$0$0$21,000
Net income-$8.92M-$8.95M-$7.61M$57.73M-$7.39M-$9.49M-$11.03M-$14.19M
EBITDA-$10.56M-$9.02M-$7.63M$45.97M-$7.48M-$9.07M-$12.11M-$14.41M
EPS (basic)-0.26-0.44-0.54—-0.60-0.78-0.90—
EPS (diluted)-0.26-0.44-0.54—-0.60-0.78-0.90—
Weighted avg. shares (diluted)34.02M20.34M14.10M—12.24M12.20M12.20M—
Banking
Net interest income—-$246,000-$192,000$1.93M-$220,000-$284,000-$371,000$5.00M
Balance sheet
Cash & equivalents$289.59M$106.27M$50.75M$48.30M$49.04M$54.83M$65.48M$78.61M
Short-term investments———————$0
Current assets$291.13M$109.65M$57.20M$55.05M$50.81M$58.32M$68.63M$81.88M
PP&E, net$827,000$804,000$889,000$979,000$1.07M$1.16M$1.25M$1.37M
Total assets$297.20M$115.87M$63.67M$61.78M$57.78M$66.12M$79.07M$92.33M
Current liabilities$5.17M$5.40M$10.67M$11.35M$11.11M$11.53M$14.58M$16.46M
Total liabilities$9.53M$9.96M$17.36M$19.76M$76.23M$78.35M$83.08M$86.66M
Shareholders' equity$287.67M$105.91M$46.31M$42.01M-$18.45M-$12.23M-$4.01M$5.67M
Shares outstanding29.89M23.74M14.63M12.86M12.30M12.20M12.20M12.20M
Cash flow statement
Operating cash flow-$4.42M-$3.08M-$6.34M-$6.18M-$4.23M-$10.65M-$12.48M-$11.43M
Capital expenditure———$0$0——$2,000
Free cash flow———-$6.18M-$4.23M——-$11.43M
Investing cash flow-$52,000$0$0$7.00M$0$0$0-$2,000
Financing cash flow$187.79M$58.59M$8.80M-$1.56M-$1.56M——$317,000
Depreciation & amortization$100,000$100,000$90,000$90,000$100,000$100,000$119,000$120,000
Stock-based compensation$2.90M$1.69M$1.55M$1.47M$1.18M$1.27M$1.34M$1.25M

Free plan shows the latest 8 periods; Pro shows all 39 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.